CFGI’s Capital Markets team assisted Oculis Holding AG (“Oculis”) with its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp.
CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.
CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.
CFGI’s Capital Markets team assisted privately-owned BCP Raptor Holdco LP (“BCP”), the parent company of EagleClaw Midstream, with the completion of an all-stock business combination with Altus Midstream Company (Nasdaq: ALTM) (“Altus”), creating a unique, fully-integrated midstream company.
2021 was a year of tremendous change and growth for CFGI.
2021 was an exciting year of growth for CFGI, which included a new partnership with CVC Capital Partners, one of the world’s largest private equity firms.
2021 was an exciting year for CFGI; we announced a new partnership with CVC alongside current partner The Carlyle Group, saw significant growth in the business and can now announce the largest promotion class to date.
CFGI’s Capital Markets team assisted Enjoy Technology, Inc.